Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune)

NCT05498272 is registered in ClinicalTrials.gov with Rana McKay, MD as lead sponsor.

NCT NCT05498272
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05498272 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of Neoadjuvant PARP Inhibition Followed by Radical Prostatectomy in Patients With Unfavorable Intermediate-Risk or High-Risk Prostate Cancer With Select HRR Gene Alterations (NePtune)
Lead sponsor
Rana McKay, MD
Phase
Phase 2
Overall status
Active, not recruiting
Start date
February 1, 2023
Completion date
December 31, 2026
Enrollment
32 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

brca1 mutation, brca2 mutation, high-risk cancer, prostate cancer, prostatic adenocarcinoma